GlassScriptPhysician profile
Savi Mushiyev
NPI 1013179050
$28,159.64
in general payments reported to CMS, 2019-2025
32 companies · $5,320 in 2025
The $5,320 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,852 · 2020: $1,397 · 2021: $1,540 · 2022: $1,752 · 2023: $1,597 · 2024: $14K · 2025: $5,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,275 · Food and Beverage: $5,643 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,084 · Travel and Lodging: $1,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,275.00 |
| Food and Beverage | $5,643.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,084.25 |
| Travel and Lodging | $1,616.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $11,789.61 | 2020-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Amgen INC. | $5,114.72 | 2019-2025 | Repatha, Repatha |
| Biotronik INC. | $2,200.21 | 2019-2025 | Biomonitor |
| Abbott Laboratories | $1,713.30 | 2020-2024 | Pressurewire, Gallant |
| Janssen Pharmaceuticals, INC | $863.18 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $707.69 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $646.42 | 2019 | |
| Medtronic Vascular, INC. | $512.80 | 2019 | |
| Merck Sharp & Dohme LLC | $512.41 | 2021-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $408.55 | 2019-2025 | Amvuttra, Onpattro |
| Boston Scientific Corporation | $401.77 | 2019-2024 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $394.17 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $354.28 | 2019-2025 | Ozempic |
| Pfizer INC. | $302.06 | 2019-2024 | |
| Neurelis, INC. | $300.00 | 2023-2024 | Valtoco |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $288.62 | 2019-2025 | Camzyos |
| Esperion Therapeutics, INC. | $229.57 | 2020-2024 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $170.52 | 2019-2022 | |
| Heartflow, INC. | $170.42 | 2022-2025 | |
| Medtronic, INC. | $158.67 | 2022 | |
| Sk Life Science, INC. | $124.99 | 2022 | |
| Lilly USA, LLC | $121.07 | 2024-2025 | Mounjaro, Zepbound |
| Scpharmaceuticals INC. | $104.91 | 2024-2025 | |
| Irhythm Technologies, INC. | $94.06 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Philips North America LLC | $92.82 | 2023 | (Ck4) Mcot |
| Stereotaxis INC | $85.15 | 2019 | |
| Abiomed | $81.86 | 2025 | |
| Astellas Pharma US INC | $73.92 | 2020-2022 | |
| Lantheus Medical Imaging, INC. | $72.52 | 2022 | |
| Bracco Diagnostics INC. | $26.05 | 2025 | |
| Medicomp INC | $23.51 | 2025 | Telepatch Cardiac Monitor |
| Amarin Pharma, INC. | $19.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Savi Mushiyev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.